http://www.zibb.com/all/theme/cq/Medarex+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Thu, 14 May 2009 11:51:19 GMTThu, 14 May 2009 11:51:19 GMT608831http://www.zibb.com/all/theme/cq/Medarex+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.bio-medicine.org/medicine-technology-1/Medarex-Announces-Primary-Endpoint-Achieved-in-MDX-1100-Anti-IP-10-Antibody-Phase-2-Trial-for-Rheumatoid-Arthritis-4364-1/...Top-line data indicate statistically significant improvement in ACR20 ... ...PRINCETON N.J. May 14 /- Medarex Inc. (Nasda... ...,Medarex,Announces,Primary,Endpoint,Achieved,in,MDX-1100,Anti-IP-10,Antibody,Phase,2,Trial,for,Rheumatoid,Arthritis,medicine,advanced medical technology,medicalhttp://www.bio-medicine.org/medicine-technology-1/Medarex-Announces-Primary-Endpoint-Achieved-in-MDX-1100-Anti-IP-10-Antibody-Phase-2-Trial-for-Rheumatoid-Arthritis-4364-1/Medarex IncorporatedThu, 14 May 2009 11:51:19 GMThttp://www.avalonrx.com/Overview Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Our lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development.http://www.avalonrx.com/Medarex Incorporatedhttp://www.zibb.com/all/theme/cq/Medarex+IncorporatedMedarex - In the News Medarex Announces 2008 Fourth Quarter and Year End Financial Results Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009 Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drughttp://www.zibb.com/all/theme/cq/Medarex+IncorporatedMedarex Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=MEDX&sid=7753Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=MEDX&sid=7753Medarex Incorporatedhttp://www.forbes.com/feeds/ap/2009/02/02/ap5995866.htmlMedimmune will study MEDI-546 as a possible treatment for scleroderma, a chronic autoimmune disease characterized by hardening and thickening of the skin and other organs.http://www.forbes.com/feeds/ap/2009/02/02/ap5995866.htmlMedarex Incorporatedhttp://www.ariusresearch.com/curr.htmlIn September 2003, ARIUS entered into an agreement with PDL for a three-year collaboration to discover, develop and commercialize antibodies for cancer treatment.http://www.ariusresearch.com/curr.htmlMedarex Incorporatedhttp://www.copcap.com/composite-6870.htmThe new biotech company Genesto A/S, has announced a collaboration with Medarex, Inc. The two companies announced a collaboration for the development of fully human therapeutic antibodies.http://www.copcap.com/composite-6870.htmMedarex Incorporatedhttp://www.biz-lib.com/ZEB67239.htmlOver 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.http://www.biz-lib.com/ZEB67239.htmlMedarex Incorporatedhttp://www.htscreening.net/index.aspx?ID=34878Euroscreen s.a. announced it has acquired an exclusive license from ICOS Corporation for key patents relating to the human CCR5 receptor and its role in HIV infection. The ICOS patents U.S. 6,265,184, U.S.http://www.htscreening.net/index.aspx?ID=34878Medarex Incorporatedhttp://www.apria.com/resources/1,2725,494-854724,00.htmlPRINCETON, N.J., Dec 03, 2008 /PRNewswire-FirstCall via COMTEX/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the RBC Capital Markets Healthcare Conference at 3:30 p.m. Eastern Time on Wednesday, December 10, 2008.http://www.apria.com/resources/1,2725,494-854724,00.htmlMedarex Incorporatedhttp://www.quotelinks.com/companies/medx.htmlStock quotes, news and charts for Medarex, Inc. Quotes Simple Charts Stock News MSN Investor Thomson Investors Short Interest Yahoo Finance CBS Marketwatch BigCharts StockCharts.com Yahoo Lycos Investing Quicken Yahoo News Quote.com (Lycos) CNET news ZDNet Business Week Stock earnings,http://www.quotelinks.com/companies/medx.htmlMedarex Incorporatedhttp://www.aviron.com/pipeline/collaborations.aspMedImmune is advancing a pipeline of promising candidates in the areas of infectious disease, oncology and immunology. We are also actively seeking new opportunities and technologies to add to this pipeline.http://www.aviron.com/pipeline/collaborations.aspMedarex Incorporatedhttp://www.fibrogen.com/news/fg19980729.htmlAnnandale, NJ; South San Francisco, CA; JULY 29, 1998 -- Medarex, Inc. (NASDAQ: MEDX) and FibroGen, Inc., a privately held biotechnology company, announced today that they have entered into an antibody development agreement for potential anti-fibrotic therapies.http://www.fibrogen.com/news/fg19980729.htmlMedarex Incorporatedhttp://www.evaluatepharma.com/CoInfo/CoInfo-MDX.htmEvaluatePharma provides historic and forecast sales from 1986 to 2010 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO.http://www.evaluatepharma.com/CoInfo/CoInfo-MDX.htmMedarex Incorporatedhttp://www.genmab.com/CompanyInformation/PartnerShips.aspxGenomics and other research techniques, such as proteomics, are leading to the discovery of an unprecedented number of potential disease targets. Genmab’s ability to quickly convert interesting targets into antibody products has attracted numerous partners.http://www.genmab.com/CompanyInformation/PartnerShips.aspxMedarex Incorporatedhttp://www.diadexus.com/press_room/01_29_03.shtmlPRINCETON, N.J. and SOUTH SAN FRANCISCO, Calif., Jan. 29 /PRNewswire- FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) and diaDexus, Inc. today announced a collaboration for the research and development of fully human antibody therapeutics.http://www.diadexus.com/press_room/01_29_03.shtmlMedarex Incorporatedhttp://www.celera.com/celera/pr_1150954266Celera Genomics and Medarex Establish Therapeutic Antibody Collaboration in Cancer Collaboration Combines Celera s Protein Discoveries with Medarex s Expertise in Developing Fully Human Antibody Therapeutics ROCKVILLE, MD, and PRINCETON, N.J., - June 22, 2006http://www.celera.com/celera/pr_1150954266Medarex Incorporatedhttp://www.biotk.com/directory_details.php?iden=145Presentation: Medarex, Inc., founded in 1987, is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases.http://www.biotk.com/directory_details.php?iden=145Medarex Incorporatedhttp://moneycentral.msn.com/companyreport?symbol=MEDXMedarex Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of fully human antibody-based therapeutic product candidates.http://moneycentral.msn.com/companyreport?symbol=MEDXMedarex Incorporatedhttp://www.cheviotartus.co.uk/pre_employment_questionnaires/pre_employment_questionnaires_268.htmlPRINCETON, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it plans to present at NASDAQs 16th Investor Program at 10:00 AM Eastern Time on December 8, 2005. The conference is being held at The Renaissance Chancery Court Hotel in London, England.http://www.cheviotartus.co.uk/pre_employment_questionnaires/pre_employment_questionnaires_268.htmlMedarex Incorporatedhttp://uk.finance.yahoo.com/q?s=MEDXCopyright 2007 (c) Yahoo! UK Ltd. All rights reserved. Questions | Disclaimer | Quotes Information Quotes delayed except where indicated otherwise. Delay time is 20 mins for London stock exchange. See also delay times for other exchanges.http://uk.finance.yahoo.com/q?s=MEDXMedarex Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=318212006 JUL 21 - (NewsRx.com) -- Celera Genomics (CRA), an Applera Corp. business, and Medarex, Inc., (MEDX) announced the formation of a strategic collaboration to discover and develop fully human antibodies for the potential treatment of multiple cancer indications.http://www.pharmacychoice.com/News/article.cfm?Article_ID=31821Medarex Incorporatedhttp://www.cov.com/news/detail.aspx?news=1013The Covington team was led by corporate lawyers Simon Goodworth and Simon Gamblin in London, and the Medarex team by Beth Behrend, Deputy General Counsel and Brad Middlekauff, General Counsel. Dwight A. Kinsey of Satterlee Stephens Burke & Burke advised on U.S .law aspects of the transaction.http://www.cov.com/news/detail.aspx?news=1013Medarex Incorporatedhttp://www.diversa.com/Pages/AboutUs/AboutUsAllianceMedarex.htmlIn October 2003, Diversa and Medarex announced a strategic partnership aimed at developing antibodies with enhanced functionality. Through a joint research effort, Diversa and Medarex planned to combine their respective capabilities in directed evolution and antibody biology.http://www.diversa.com/Pages/AboutUs/AboutUsAllianceMedarex.htmlMedarex Incorporatedhttp://www.smartbrief.com/news/industryPR-detail.jsp?id=398AB0D5-10C8-4A54-A40E-C7D19674185Fannounced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1401, a fully human antibody that targets CD30-positive lymphomas.http://www.smartbrief.com/news/industryPR-detail.jsp?id=398AB0D5-10C8-4A54-A40E-C7D19674185FMedarex Incorporated